The Trump administration is reviewing a contract extended to Moderna in the final days of the Biden administration.
Moderna Inc.'s stock tumbled 4% Thursday, after a report that health officials are reviewing a contract the company won from the Biden administration to support its efforts to develop a bird-flu ...
U.S. stock indexes are slipping, and Wall Street remains subdued following a rough run where worries about the economy ...
Moderna (NASDAQ: MRNA) became a hot investment during the pandemic as its COVID vaccine made investors bullish on its future.
US health officials are reevaluating a $590 million contract for bird flu shots that the Biden administration awarded to ...
The FDA canceled a vaccine advisory committee meeting to discuss influenza virus strains that should be included in shots for ...
The administration also told Vaxart Inc. to halt its research on an oral Covid vaccine, Bloomberg reports. In related news, the policy to cull poultry caught in H5N1 bird flu outbreaks will not be ...
Shares of vaccine maker Moderna dropped more than 5% late Wednesday after reports that the Health and Human Services ...
Moderna’s reliance on its COVID vaccine for revenue has become a vulnerability as sales decline and the company invests heavily in its product pipeline. The bird flu vaccine contract was expedited due ...
A modest vertical extension on Rue du Petit-Musc by Mir Architectes embodies the vision of the City of Paris for a greener ...
The U.S. government awarded Moderna $590 million in January to advance the development of its bird flu vaccine ...
U.S. health officials are reevaluating a $590M bird flu vaccine contract that was awarded to Moderna ( NASDAQ: MRNA) by the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback